In contrast, after adding 20 mg/kg of monoclonal antibody against CD40 ligand to the regimen on days 0 and 2, we observed four thromboembolic complications in nine recipients. These included two ...

CD40 agonistic antibodies mimic the natural interaction between the CD40 receptor and its ligand, CD40L, triggering immune responses through cytokine release and T-cell activation. This approach ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

“We have been researching precision medicine for close to 15 years now, as well as how we can use antibodies to influence an ...

LUND, SWEDEN / ACCESS Newswire / March 21, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end of ...

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...

Abiprubart, an antibody that inhibits the signaling between CD40 and CD154, was in development in a competitive niche but Kiniksa had previously presented that as a positive. Last month ...

Pfizer seems to have stopped development of its antibody-drug conjugate cifurtilimab (SEA-CD40), inherited as part of its takeover of Seagen.

The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...